Breast cancer patients with dense breast tissue have almost a two-fold increased risk of developing disease in the contralateral breast, according to new research from The University of Texas MD Anderson Cancer.
Eric Prossnitz, PhD and his team uncovered new details of the aging process. They discovered an altered balance between certain signaling molecules in the smooth muscle cells of blood vessels and the heart. The team also discovered a new class of drugs that combats an important part of the aging process.
The University of Texas MD Anderson Cancer Center returns to Southern California this month with its Making Cancer History® Seminar, 3:30-5:30 p.m. Feb. 20 at the Renaissance Indian Wells Resort and Spa, 44400 Indian Wells Lane.
Yale researchers found in a study that one in four high schoolers who use electronic cigarettes are inhaling vapors produced by dripping e-liquids directly onto heating coils, instead of inhaling from the e-cigarette mouthpiece, possibly increasing exposure to toxins and nicotine.
Paulovich’s lab will develop a customized panel of MRM (multiple reaction monitoring)-based assays and deploy these assays to quantify tumor proteins in clinical samples from patients receiving treatment. Other collaborators in the Moonshot project will decide on treatments, track how well the treatments shrink the tumors, and then search for correlations that show whether the tumors’ protein makeup related to how well the patients responded to treatment.
A new method has been found for identifying therapeutic targets in cancers lacking specific key tumor suppressor genes. The process, which located a genetic site for the most common form of prostate cancer, has potential for developing precision therapy for other cancers, such as breast, brain and colorectal, say researchers at The University of Texas MD Anderson Cancer Center. Study results were published in the Feb. 6 online issue of Nature.
In honor of World Cancer Day on Feb. 4, The University of Texas MD Anderson Cancer Center calls for health care providers, organizations, governments and individuals to unite in the common goal of eliminating cancer. Driven to accelerate progress toward Making Cancer History®, MD Anderson is proud to support this global effort.
• New Roswell Park spinoff company will develop next-generation cancer immunotherapies
• Novel approach combines unique adoptive T cell therapy with genetically engineered stem cell therapy
• Clinical trial planned in ovarian, pancreatic, lung, prostate and other hard-to-treat cancers
NCCN has published the NCCN Guidelines for Patients® and NCCN Quick Guide™ sheet for Waldenström’s Macroglobulinemia—a rare, but manageable type of Non-Hodgkin’s Lymphoma.
Georgetown Lombardi Comprehensive Cancer Center researchers have used animal models to reveal new information about the impact – positive and negative – that soy consumption could have on a common breast cancer treatment.
Tudor Oprea, MD, PhD, at UNM Comprehensive Cancer Center and his collaborators from the UK-based European Bioinformatics Institute in Hinxton and from the Institute for Cancer Research in London have created the beginnings of an open archive that links a drug’s chemical structure, its molecular biology activity and the diseases it is used to treat.
The University of Texas MD Anderson Cancer Center and Guardant Health today announced a multi-year partnership designed to accelerate comprehensive liquid biopsy technology into the standard of care in cancer treatment.
Researchers have uncovered 30 genes that could, one day, serve as therapeutic targets to reverse Rett syndrome, a rare neurological disorder that affects only girls and is a severe form of an autism spectrum disorder.
In a second human case, a Yale-led research team has found that a melanoma cell and a white blood cell can fuse to form a hybrid with the ability to metastasize. The finding provides further insight into how melanoma and other cancers spread from solid tumors with implications for future treatment.
What if doctors could look into a crystal ball and predict which of their patients might be at risk of getting sick enough to go to the emergency room? For at least one group of patients, that’s exactly what researchers at Penn Medicine are trying to do.
Today, after a yearlong review and collaborative process, Miami Cancer Institute at Baptist Health South Florida became a full member of the Memorial Sloan Kettering (MSK) Cancer Alliance. Miami Cancer Institute is the third member of the MSK Cancer Alliance, a transformative initiative that aims to improve the quality of care and outcomes for people with cancer in community settings.
Researchers at Dana-Farber Cancer Institute led a study that provides some of the strongest evidence to date that microorganisms living in the large intestine can serve as a link between diet and certain types of colorectal cancer.
NCCN’s second policy and advocacy fellow will maintain a comprehensive understanding of the oncology policy landscape, contribute to the advancement of NCCN’s policy initiatives, and contribute to the monitoring and awareness of use of NCCN Content by public and private payers to enhance access to and delivery of quality oncology care in the United States.
BUFFALO, N.Y. — More than 1 in 4 adults and nearly 1 in 10 youth use tobacco, according to findings from the Population Assessment of Tobacco and Health (PATH) Study, published online ahead of print in the New England Journal of Medicine. The PATH Study, established in 2011 through collaboration between the National Institutes of Health’s National Institute on Drug Abuse and the U.S. Food and Drug Administration’s Center for Tobacco Products, is a uniquely large, nationally representative longitudinal study designed to examine tobacco use behaviors and health among the U.S. population over multiple years of follow-up. The PATH Study is being conducted by Westat of Rockville, Md., with Roswell Park Cancer Institute as the scientific lead.
The University of Kansas Cancer Center and Children’s Mercy Hospital have announced four first-of-their-kind endowed chair appointments that will help eliminate childhood diseases around the world.
Scientists at Washington University School of Medicine in St. Louis have exploited a common weak point in cancer cell metabolism, forcing tumor cells to reveal the backup fuel supply routes they rely on when this weak point is compromised. Mapping these secondary routes, the researchers also identified drugs that block them. They now are planning a small clinical trial in cancer patients to evaluate this treatment strategy.
Researchers at The University of Kansas Cancer Center have found that high doses of drugs commonly used to fight high cholesterol can destroy a rogue protein produced by a damaged gene that is associated with nearly half of all human cancers
In a new study, researchers at the Perelman School of Medicine at the University of Pennsylvania have illuminated one of pancreatic cancer’s major resistance mechanisms: a form of inflammation that is triggered by the tumor in response to treatment and helps keep tumor cells alive. Blocking this inflammation after radiation therapy brought a significant improvement in survival in a mouse model of the disease.
Metastasis, or spread of a tumor from the site of origin to additional organs, causes the vast majority of cancer-related deaths, but our understanding of the molecular mechanisms behind metastasis remains limited. A research team led by Dean Tang, PhD, Chair of the Department of Pharmacology and Therapeutics at Roswell Park Cancer Institute, examined the multistep process that leads to metastasis and their work, which illuminates the role of prostate cancer stem cells that promote tumor growth and metastasis, has been published online ahead of print in the journal Nature Communications.
Fred Hutchinson Cancer Research Center announced Miami Marlins pitcher Dustin McGowan has been named the 52nd annual Hutch Award winner. The award is given yearly to a Major League Baseball player who best exemplifies the honor, courage and dedication of the legendary baseball player and manager Fred Hutchinson, for whom the cancer research center was named.
A five-year, $1.8 million grant (R01CA203965) from the National Cancer Institute awarded to Rutgers Cancer Institute of New Jersey resident research member Wenwei Hu, PhD, will support research to further explore how chronic stress impacts cancer development.
Cancer cells often delete genes that normally suppress tumor formation. These deletions also may extend to neighboring genes, an event known as “collateral lethality,” which may create new options for development of therapies for several cancers.
Recognizing a critical need to improve national vaccination rates for the human papillomavirus (HPV), UC Davis Comprehensive Cancer Center has again united with each of the 69 National Cancer Institute (NCI)-designated cancer centers in issuing a joint statement in support of recently revised recommendations from the U.S. Centers for Disease Control and Prevention (CDC)
Researchers at Seattle’s Fred Hutchinson Cancer Research Center and the University of Washington say a new study suggests ways to improve immune therapy for certain cancers including a virus-associated form of Merkel cell carcinoma, a rare, aggressive skin cancer.
Findings uncover an ancient mechanism that makes cancer cells invasive, explains melanoma’s resistance to therapy and opens the door to development of novel cancer therapies
Recognizing a critical need to improve national vaccination rates for the human papillomavirus (HPV), Yale Cancer Center has again united with each of the 69 National Cancer Institute (NCI)-designated cancer centers in issuing a joint statement in support of recently revised recommendations from the Centers for Disease Control and Prevention (CDC).
A new therapy in development for the treatment of midgut neuroendocrine tumors, a rare type of cancer that occurs in the small intestine and colon, shows improved progression-free survival and response rates for patients with advanced disease. Results of the international phase 3 clinical trial of lutetium-177 (177Lu)-Dotatate compared to high-dose octreotide LAR were published in the Jan. 12 issue of the New England Journal of Medicine.
TAMPA, Fla. – Graft-versus-host-disease (GVHD) is the leading cause of non-relapse associated death in patients who receive stem cell transplants. In a new study published as the cover story in Science Translational Medicine, Moffitt Cancer Center researchers show that a novel treatment can effectively inhibit the development of GVHD in mice and maintain the infection- and tumor-fighting capabilities of the immune system.
Vescor LLC, a new company focused on discovery and development of autophagy targeted therapeutics for cancer treatment, has been formed by The University of Texas MD Anderson Cancer Center, Deerfield Management and two leading autophagy experts.
As the nation's 69 National Cancer Institute-designated cancer centers come together in support of recently updated HPV vaccination recommendations, a Rutgers Cancer Institute of New Jersey gynecologic oncologist shares insight on how this vaccine can help prevent cervical cancer.
As national vaccination rates for the human papillomavirus (HPV) remain low, The University of Texas MD Anderson Cancer Center has again united with the 68 other National Cancer Institute (NCI)-designated cancer centers in issuing a joint statement endorsing the recently revised vaccination recommendations from the Centers for Disease Control and Prevention (CDC).
Standard therapy for prostate cancer, the third-leading cause of cancer-related deaths in American men, is based on blocking androgens, the male sex hormones. However, for some men, prostate cancer recurs despite androgen-deprivation therapy. A team of scientists led by Irwin Gelman, PhD, Professor of Oncology in the Department of Cancer Genetics at Roswell Park Cancer Institute, has identified an 11-gene signature unique to advanced recurrent prostate cancer that they believe will help to identify these aggressive and potentially fatal prostate cancers sooner. The findings have been published online ahead of print in the journal Oncotarget.
Twenty-seven percent of 50 heavily pretreated patients with stage IV breast cancer saw clinical benefit from the drug, with at least “stable disease” at 24 or more weeks after the start of treatment.